Search

Author/Creator Luthringer, Remy

4. A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity. (June 2018)

Authors:
De Boer, Peter; Drevets, Wayne C; Rofael, Hany; van der Ark, Peter; Kent, Justine M; Kezic, Iva; Parapatics, Silvia; Dorffner, Georg; van Gerven, Joop; Beneš, Heike; Keicher, Christian; Jahn, Holger; Seiden, David J; Luthringer, Remy
Journal:
Journal of psychopharmacology
Issue:
Volume 32:Number 6(2018)
Page Start:
668
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Efficacy and Safety of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia. (25th February 2022)

Authors:
Davidson, Michael; Saoud, Jay; Staner, Corinne; Noel, Nadine; Werner, Sandra; Luthringer, Elisabeth; Walling, David; Weiser, Mark; Harvey, Philip D; Strauss, Gregory P; Luthringer, Remy
Journal:
Schizophrenia bulletin
Issue:
Volume 48:Number 3(2022)
Page Start:
609
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Issues and Perspectives in Designing Clinical Trials for Negative Symptoms in Schizophrenia: Consensus Statements. Issue 1 (15th February 2020)

Authors:
Marder, Stephen R; Davidson, Michael; Zaragoza, Silvia; Kott, Alan; Khan, Anzalee; Wang, Xingmei; Velligan, Dawn I; Umbricht, Daniel; Luthringer, Remy; Daniel, David
Journal:
Schizophrenia bulletin open
Issue:
Volume 1:Issue 1(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Issues and Perspectives in Designing Clinical Trials for Negative Symptoms in Schizophrenia: Consensus Statements. Issue 1 (15th February 2020)

Authors:
Marder, Stephen R; Davidson, Michael; Zaragoza, Silvia; Kott, Alan; Khan, Anzalee; Wang, Xingmei; Velligan, Dawn I; Umbricht, Daniel; Luthringer, Remy; Daniel, David
Journal:
Schizophrenia bulletin open
Issue:
Volume 1:Issue 1(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Network Analysis Indicates That Avolition Is the Most Central Domain for the Successful Treatment of Negative Symptoms: Evidence From the Roluperidone Randomized Clinical Trial. (28th January 2020)

Authors:
Strauss, Gregory P; Zamani Esfahlani, Farnaz; Sayama, Hiroki; Kirkpatrick, Brian; Opler, Mark G; Saoud, Jay B; Davidson, Michael; Luthringer, Remy
Journal:
Schizophrenia bulletin
Issue:
Volume 46:Number 4(2020)
Page Start:
964
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia. (February 2019)

Authors:
Brooks, Sander; Jacobs, Gabriël E; de Boer, Peter; Kent, Justine M; Van Nueten, Luc; van Amerongen, Guido; Zuiker, Rob; Kezic, Iva; Luthringer, Remy; van der Ark, Peter; van Gerven, Joop MA; Drevets, Wayne
Journal:
Journal of psychopharmacology
Issue:
Volume 33:Number 2(2019)
Page Start:
202
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗